Type 2 diabetes

The SURPASS-PEDS Phase 3 trial evaluated Mounjaro (tirzepatide) in pediatric patients (10-17) with type 2 diabetes. Mounjaro significantly reduced A1C and BMI compared to placebo after 30 weeks, improvements sustained through 52 weeks. 86.1% of subjects on 10mg Mounjaro achieved an A1C target ≤6.5%. The safety profile was consistent with adult studies. Lilly seeks regulatory approval to expand Mounjaro’s label for this younger population, addressing a critical unmet need given the rise of type 2 diabetes in children.

Lilly announced positive Phase 3 trial results for once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes. The QWINT-1, QWINT-3, and QWINT-4 trials demonstrated non-inferior A1C reduction compared to daily basal insulin. The company plans to submit efsitora for regulatory review by the end of the year.

Eli Lilly announced positive Phase 3 results for orforglipron, a once-daily oral drug for type 2 diabetes. The ACHIEVE-1 trial showed the drug lowered A1C levels (1.3-1.6% reduction) in four weeks and promoted weight loss (up to 7.9%). The safety profile was consistent with existing GLP-1 medications. Lilly plans further studies, positioning orforglipron as a potential competitor in the diabetes and weight-loss treatment market.